Clinical Trials Directory

Trials / Completed

CompletedNCT04670328

Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity

Status
Completed
Phase
Study type
Observational
Enrollment
101 (actual)
Sponsor
FMH College of Medicine and Dentistry · Academic / Other
Sex
All
Age
17 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.

Detailed description

Objective: COVID-19 virus involves respiratory as well as other body systems including cardiovascular, gastrointestinal, neurological, immunological and hematopoietic system. Patient of covid-19 pneumonia presents with wide range of hemostatic abnormalities. These hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity. Material and Method: This was a retrospective study, conducted in Department of Pathology and Department of medicine, FMH college of Medicine and Dentistry from May 2020 to July 2020. Total of 101, confirmed cases of covid-19 disease, both genders between 17 to 75-year age were included. Hematological parameters were compared in mild, moderate, severe and critical disease group. Continuous variables were analyzed by using non parametric, Kruskal Wallis test while categorical variables were analyzed by chi-square test.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTnot requiredDiagnostic tests( hematological parameters) were assessed.

Timeline

Start date
2020-05-01
Primary completion
2020-07-31
Completion
2020-07-31
First posted
2020-12-17
Last updated
2020-12-17

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT04670328. Inclusion in this directory is not an endorsement.